Pier Paolo Scaglioni

Pier Paolo Scaglioni

Auto-generated profile, based on publicly available information

Pier Paolo Scaglioni

Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2006 in Molecular Cell
Verified
Journal Article
Closed access
TSTian Huai Shen
Tian Huai Shen
HLHui-Kuan Lin
Hui-Kuan Lin
PSPier Paolo Scaglioni
Pier Paolo Scaglioni
TYThomas M. Yung
Thomas M. Yung
PPPier Paolo Pandolfi
Pier Paolo Pandolfi

1 December 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JSJames P. Sullivan
James P. Sullivan
MSMonica Spinola
Monica Spinola
MDMichael Dodge
Michael Dodge
MRMaria G. Raso
Maria G. Raso
CBCarmen Behrens
Carmen Behrens
JMJohn D. Minna
John D. Minna
Aldehyde dehydrogenase (ALDH) is a candidate marker for lung cancer cells with stem cell-like properties. Immunohistochemical staining of a large panel of primary non–small cell lung cancer (NSCLC) samples for ALDH1A1, ALDH3A1, and CD133 revealed a significant correlation between ALDH1A1 (but not ALDH3A1 or CD133) expression and poor prognosis in patients including those with stage I and N0 disease. Flow cytometric analysis of a panel of lung cancer cell lines and patient tumors revealed that most NSCLCs contain a subpopulation of cells with elevated ALDH activity, and that this activity is associated with ALDH1A1 expression. Isolated ALDH+ lung cancer cells were observed to be highly tumorigenic and clonogenic as well as capable of self-renewal compared with their ALDH− counterparts. Expression analysis of sorted cells revealed elevated Notch pathway transcript expression in ALDH+ cells. Suppression of the Notch pathway by treatment with either a γ-secretase inhibitor or stable expression of shRNA against NOTCH3 resulted in a significant decrease in ALDH+ lung cancer cells, commensurate with a reduction in tumor cell proliferation and clonogenicity. Taken together, these findings indicate that ALDH selects for a subpopulation of self-renewing NSCLC stem-like cells with increased tumorigenic potential, that NSCLCs harboring tumor cells with ALDH1A1 expression have inferior prognosis, and that ALDH1A1 and CD133 identify different tumor subpopulations. Therapeutic targeting of the Notch pathway reduces this ALDH+ component, implicating Notch signaling in lung cancer stem cell maintenance. Cancer Res; 70(23); 9937–48. ©2010 AACR.

7 May 2006 in Nature
Verified
Journal Article
Open access
PDF file
LTLloyd C. Trotman
Lloyd C. Trotman
AAAndrea Alimonti
Andrea Alimonti
PSPier Paolo Scaglioni
Pier Paolo Scaglioni
JKJason A. Koutcher
Jason A. Koutcher
CCCarlos Cordon-Cardo
Carlos Cordon-Cardo
PPPier Paolo Pandolfi
Pier Paolo Pandolfi
The proto-oncogene AKT (also known as PKB) is activated in many human cancers, mostly owing to loss of the PTEN tumour suppressor1. In such tumours, AKT becomes enriched at cell membranes where it is activated by phosphorylation. Yet many targets inhibited by phosphorylated AKT (for example, the FOXO transcription factors) are nuclear; it has remained unclear how relevant nuclear phosphorylated AKT (pAKT) function is for tumorigenesis. Here we show that the PMLtumour suppressor prevents cancer by inactivating pAKT inside the nucleus. We find in a mouse model that Pml loss markedly accelerates tumour onset, incidence and progression in Pten-heterozygous mutants, and leads to female sterility with features that recapitulate the phenotype of Foxo3a knockout mice2. We show that Pml deficiency on its own leads to tumorigenesis in the prostate, a tissue that is exquisitely sensitive to pAkt levels, and demonstrate that Pml specifically recruits the Akt phosphatase PP2a as well as pAkt into Pml nuclear bodies. Notably, we find that Pml-null cells are impaired in PP2a phosphatase activity towards Akt, and thus accumulate nuclear pAkt. As a consequence, the progressive reduction in Pml dose leads to inactivation of Foxo3a-mediated transcription of proapoptotic Bim and the cell cycle inhibitor p27kip1. Our results demonstrate that Pml orchestrates a nuclear tumour suppressor network for inactivation of nuclear pAkt, and thus highlight the importance of AKT compartmentalization in human cancer pathogenesis and treatment.

1 February 1998 in Hepatology
Verified
Journal Article
Open access
PDF file
MMMargherita Melegari
Margherita Melegari
PSPier Paolo Scaglioni
Pier Paolo Scaglioni
JWJack R. Wands
Jack R. Wands
Hepatitis B virus (HBV) variant strains may develop during therapy for chronic infection with the nucleoside analog 2′,3′-dideoxy-3′-thiacytidine (3TC). HBV mutants result from isoleucine (I) or valine (V) substitutions in the methionine (M) of the YMDD motif in the viral reverse-transcriptase catalytic domain. In addition, other mutations in the reverse-transcriptase “B domain” involving either a phenylalanine (F)-to-leucine (L) at amino acid 501 (F501L) or an L-to-M substitution at amino acid 515 (L515M) have been observed during 3TC and Famciclovir therapy as well. To determine the biologic consequences of these mutations on viral replication, variant viral genomes were constructed and transiently transfected into hepatocellular carcinoma (HCC) and HEK 293 human embryo kidney-derived cell lines. In transiently transfected HCC cells, the viruses bearing the YI/VDD or F501L mutations had greatly impaired replication as compared to wild-type virus, whereas the virus carrying the L515M substitution showed the least defect. Double mutants with the L515M substitution showed intermediate defect between the YI/VDD or F501L and the L515M single-mutant strains. In contrast, when transfected into HEK 293 cells, the viruses bearing the YI/VDD or L515M mutation replicated as wild-type. However, under conditions of deoxynucleotide depletion produced by hydroxyurea treatment of HEK 293 cells, all mutants but not the wild-type virus exhibited a reduced replication phenotype similar to that observed in HCC cells. In both HCC and HEK 293 cells, the mutant viruses carrying the F501L substitution showed a decreased pregenomic RNA encapsidation level, suggesting that the defect in HBV DNA synthesis occurs at the RNA packaging level. These findings show that 3TC and Famciclovir selected mutations alter the properties of the HBV reverse transcriptase, resulting in impaired viral replication within the cell.

13 June 2004 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
RBRosa Bernardi
Rosa Bernardi
PSPier Paolo Scaglioni
Pier Paolo Scaglioni
SBStephan Bergmann
Stephan Bergmann
HHHenning F. Horn
Henning F. Horn
KVKaren H. Vousden
Karen H. Vousden
PPPier Paolo Pandolfi
Pier Paolo Pandolfi

1 August 2016 in Cell Reports
Verified
Journal Article
Open access
MPMahesh S. Padanad
Mahesh S. Padanad
Georgia KonstantinidouGeorgia Konstantinidou
Georgia Konstantinidou
NVNiranjan Venkateswaran
Niranjan Venkateswaran
MMMargherita Melegari
Margherita Melegari
SRSmita Rindhe
Smita Rindhe
PSPier Paolo Scaglioni
Pier Paolo Scaglioni
KRAS is one of the most commonly mutated oncogenes in human cancer. Mutant KRAS aberrantly regulates metabolic networks. However, the contribution of cellular metabolism to mutant KRAS tumorigenesis is not completely understood. We report that mutant KRAS regulates intracellular fatty acid metabolism through Acyl-coenzyme A (CoA) synthetase long-chain family member 3 (ACSL3), which converts fatty acids into fatty Acyl-CoA esters, the substrates for lipid synthesis and β-oxidation. ACSL3 suppression is associated with depletion of cellular ATP and causes the death of lung cancer cells. Furthermore, mutant KRAS promotes the cellular uptake, retention, accumulation, and β-oxidation of fatty acids in lung cancer cells in an ACSL3-dependent manner. Finally, ACSL3 is essential for mutant KRAS lung cancer tumorigenesis in vivo and is highly expressed in human lung cancer. Our data demonstrate that mutant KRAS reprograms lipid homeostasis, establishing a metabolic requirement that could be exploited for therapeutic gain.